PD-1 blockade induces responses by inhibiting adaptive immune resistance. Tumeh, et al., Science (2014) Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Spranger et Nature. (2015) Roche’s PD L1 inhibitor Tecentriq: a new contender in non small cell lung cancer, Clarivate...
MELANOMAIntroduction: Phase III studies of PD-1 inhibitors have demonstrated remarkable improvements in the survival of patients with metastatic melanoma (MM). If these results are generalizable to an unselected patient population treated in clinical routine is unknown. This study aimed to investigate ...
[4]. Jesse M. Zaretsky, Angel Garcia-Diaz, Daniel S. Shin, et al. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N Engl J Med. 2016 September ; 375(9): 819–829 [5]. Johnson DB, Chandra S, Sosman JA. Immune Checkpoint Inhibitor Toxicity in 2018. JAMA...
[1]. HairRepigmentation During Immunotherapy Treatment With an Anti-Programmed Cell Death1 and Anti-Programmed Cell Death Ligand 1 Agent for Lung Cancer.JAMA Dermatol2017 Nov 1;153(11):1162-1165 [2]. Developmentof Poliosis Following Checkpoint ...
PD-1 blockade induces responses by inhibiting adaptive immune resistance. Tumeh, et al., Science (2014) Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Spranger et Nature. (2015) Roche’s PD L1 inhibitor ...
图 | “An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma”论文截图 在此次宣布的与再生元的合作中，双方计划针对 PD-1 的响应率、耐药性即复发性高等问题，在晚期黑素瘤的二线治疗方案中进行随机 II 期试验，预计在今年第三季度披露更多细节并在第四季度开始试验。“一般的癌症疫苗都需要和...
当患者出现PD-1耐药、肿瘤进展的时候，继续用药仍然是有疗效的。根据FDA对8项临床试验数据的研究，发现继续使用PD-1治疗的患者要比停止使用PD-1治疗的患者拥有更长的生存时间（24.4个月 VS 11.2个月）。要注意的是，根据NCCN指南，一线治疗（包括辅助治疗）免疫治疗快速进展及二线治疗的患者不要考虑继续用药，而...
2023年6月30日,兰州大学基础医学院王德贵教授课题组在cell death discovery上发表了题为“RNF8 enhances the sensitivity of PD-L1 inhibitor against melanoma through ubiquitination of galectin-3 in stroma”的研究。该研究基于泛素化修饰组学找到并鉴定出RNF8通过k48多泛素化修饰galectin-3,并经泛素蛋白酶体系统促进...
[6]. Milhem M,Zakharia Y, Davar D, et al. O85 Durable responses in anti-PD-1 refractorymelanoma following intratumoral injection of a toll-like receptor 9 (TLR9)agonist, CMP-001, in combination with pembrolizumab[J]. 2020.[7]. Tolcher A, HamidO, Weber J, et al. Single agent anti-...
9. Ahronian, L. G. et al. Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations. Cancer Discov. 5, 358–367 (2015).10. Kopetz, S. et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer....